AZN Efzimfotase Alfa Gets FDA Priority Review for HPP

The FDA accepted Alexion’s biologics license application for efzimfotase alfa and granted Priority Review for the treatment of hypophosphatasia (HPP) in patients 2 years and older. AstraZeneca (AZN), Alexion’s parent, announced the decision on September 18. A decision is expected in the first half of 2027.

Mechanism: Replacing the Missing Enzyme

Efzimfotase alfa (ALXN1850) is a next-generation enzyme replacement therapy that replaces the deficient alkaline phosphatase (ALP) enzyme underlying HPP, a rare inherited metabolic disease that causes defective bone mineralization, muscle weakness, pain, and fatigue. HPP is loss-of-function: patients carry mutations in the ALPL gene, so their bodies cannot make enough working ALP, the enzyme that pulls mineral into bone matrix. Without it, bones stay soft — ricket-like deformities in children, fracture risk and pain in adults — and the downstream chemistry breaks too, causing muscle weakness and, in severe cases, seizures and respiratory failure.

Enzyme replacement is the logical therapy: inject working ALP and normal mineralization resumes. The drug is designed for subcutaneous self-administration every two weeks, a convenience upgrade over Alexion’s own Strensiq (asfotase alfa), which requires up to six injections weekly. That is not a cosmetic difference for adherence: a patient moving from six shots a week to one shot every two weeks goes from 312 injections a year to 26. In the Phase 3 program, efzimfotase alfa showed five times lower annualized rates of injection-site reactions than Strensiq — meaning the new molecule is both easier to take and better tolerated at the injection site.

The Phase 3 Program Behind the Filing

The filing rests on the largest Phase 3 program ever run in HPP, spanning three trials. MULBERRY, in 29 treatment-naive children aged 2 to under 12, hit its primary endpoint with a median Radiographic Global Impression of Change score of 1.67 versus 0 for placebo. HICKORY, in 124 adolescents and adults, measured change in six-minute walk distance. CHESTNUT, in 43 children previously treated with Strensiq, measured safety and tolerability against Strensiq as the active comparator. HICKORY’s full results will be presented at the American Society for Bone and Mineral Research annual meeting later this year.

The significance is breadth. Strensiq is approved only for perinatal, infantile, and juvenile-onset HPP. Efzimfotase alfa, if approved, would be the first therapy cleared to address skeletal abnormalities and functional impairments regardless of disease onset, including the roughly 80% of HPP patients who are adults and often lack overt bone manifestations. Alexion estimates the addressable HPP population at about 13,800 patients across the US and seven other major markets.

What It Means for the Trade

AstraZeneca shares closed at $166.15; as a large-cap pharma, a single rare-disease filing moves the stock little. The trade relevance is strategic: this is Alexion defending and extending the franchise it acquired AstraZeneca-for, and the filing is a textbook self-cannibalization play. Efzimfotase alfa is filed against the company’s own incumbent product, which is the right move — if a next-generation therapy is coming for your franchise, it should come from you. The conversion story is simple: a first-line-of-reasoning upgrade (every-two-week self-injection versus six weekly shots) plus a first-ever adult label gives Alexion a reason to switch existing Strensiq patients and to find a large undiagnosed adult population that Strensiq was never indicated to reach. Watch the ASBMR presentation for the HICKORY detail: the six-minute-walk data is what anchors the adult claim, and adult labels drive rare-disease revenue more than pediatric ones do.

Risks and What Could Go Wrong

Competition is forming. BioMarin recently paid $275 million for Alesta Therapeutics to acquire ALE1, an oral HPP therapy, positioning an oral option against the injectable franchise Alexion is defending. An oral therapy, if it works in humans, is a bigger threat than any injectable, because the entire burden-of-injection argument that efzimfotase alfa rests on disappears. Strensiq remains the incumbent standard of care, and Alexion is effectively filing a next-generation drug against its own product.

Regulatory risk is modest but real. Priority Review shortens the clock but does not guarantee approval; the FDA can still issue a complete response letter if it finds the data insufficient. The HICKORY endpoint — six-minute walk distance — is a functional measure that regulators sometimes scrutinize harder than radiographic ones, and the adult HPP population has heterogeneous presentation, which complicates the claim that skeletal and functional improvements generalize across onset types.

There is also commercial execution risk: identifying and diagnosing the estimated adult HPP population is the hard part of the 13,800-patient addressable market. Adult HPP patients often lack overt bone manifestations, so the sales effort is a diagnostic-education campaign, not a drug launch. That is a slower revenue ramp than the addressable-population headline suggests, and the ASBMR data and label language will determine whether payers fund the adult segment at all.

What to watch: the PDUFA decision in the first half of 2027. If approved, efzimfotase alfa would be the first HPP treatment cleared for adults without overt bone manifestations, the largest segment of the disease.